Emergent BioSolutions (CGT)

Baltimore, MD
Hybrid — also manufactures internal programs
AAV Adenoviral
4 confirmed programs · 1 sponsors · Last scored 2026-04-02
71.0
Signal Score
○ FDA Inspections ✓ Clinical Trials (4) ✓ SEC Filings (13) ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Emergent BioSolutions (CGT)

Signal Score
71.0/100 (as of 2026-04-02)
Quality Compliance
Assessment pending
Headquarters
Baltimore, MD
Modalities
AAV, Adenoviral
Active Programs
4 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 55.0
4 active programs across 1 sponsors
Modalities: AAV, Adenoviral
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
4 active programs across 1 sponsors · Modalities: AAV, Adenoviral · 2 programs in advanced phases (Phase 2/3)
Programs 4
Sponsors1
ModalitiesAAV, Adenoviral
4 active programs across 1 sponsors
Modalities: AAV, Adenoviral
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT03160339 A Study to Assess the Safety, Pharmacodynamics, and... PHASE1 Terminated
NCT01979406 A Phase 1 Ascending Dose Study to Assess the Safety and... PHASE1 Completed
NCT00893516 CD4 in Combination With CHOP in Treating Non-cutaneous... PHASE2 Terminated
NCT00877656 HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma PHASE2/PHASE3 Completed
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability 86.0
Publicly traded — financial transparency
Strong industry presence in SEC filings (114 mentions)
Multiple manufacturing risk factors in SEC filings
Source: SEC EDGAR, press monitoring
13 SEC filings with industry mentions on record
SEC Filings13 with industry mentions
Publicly traded — financial transparency
Strong industry presence in SEC filings (114 mentions)
Multiple manufacturing risk factors in SEC filings
Capacity 76.0
2 manufacturing sites
10 facility investment mentions in SEC filings
Sites: Baltimore, MD, Bayview, MD
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
2 manufacturing sites
10 facility investment mentions in SEC filings

Financial Intelligence

8-K 2026-03-03 0 keyword mentions
View on SEC EDGAR →
10-K 2026-02-27 18 keyword mentions
"Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"Commercial products, consisting of NARCAN ® Nasal Spray and KLOXXADO ® , Anthrax – Medical Countermeasures (“MCM”) Products, Smallpox - MCM products, and Emergent Bioservices (CDMO) (“Bioservices”)."
"Bioservices We also compete for bioservices with several biopharmaceutical product R&D organizations, contract manufacturers of biopharmaceutical products (CDMOs), other bioservices organizations, and university research laboratories."
View on SEC EDGAR →
8-K 2026-02-26 0 keyword mentions
View on SEC EDGAR →
8-K 2026-01-14 0 keyword mentions
View on SEC EDGAR →
8-K 2026-01-12 0 keyword mentions
View on SEC EDGAR →
8-K 2025-12-12 0 keyword mentions
View on SEC EDGAR →
10-Q 2025-10-30 12 keyword mentions
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
View on SEC EDGAR →
10-Q 2025-08-07 12 keyword mentions
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
View on SEC EDGAR →
10-Q 2025-05-08 12 keyword mentions
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (“MCM”) Products, NARCAN ® commercial product, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
View on SEC EDGAR →
10-K 2025-03-04 16 keyword mentions
"Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"NARCAN ® commercial product, Anthrax - Medical Countermeasures (“MCM”) Products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices” )."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services (“CDMO”) portfolio."
View on SEC EDGAR →
10-Q 2024-11-07 14 keyword mentions
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following four product and service categories: NARCAN ® commercial product, Anthrax - Medical Countermeasures (“MCM”) Products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"Services Segment: Bioservices - CDMO The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as “fill/finish” services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
View on SEC EDGAR →
10-Q 2024-08-07 15 keyword mentions
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio."
"As such, the key components of the business structure include the following four product and service categories: NARCAN ® commercial product, Anthrax - Medical Countermeasures (“MCM") Products, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices")."
"Services Segment: Bioservices - CDMO The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
View on SEC EDGAR →
10-Q 2024-05-02 15 keyword mentions
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio."
"As such, the key components of the business structure include the following four product and service categories: NARCAN ® commercial product, Anthrax - Medical Countermeasures (“MCM") Products, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices")."
"Services Segment: Bioservices - CDMO The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
View on SEC EDGAR →
Source: SEC EDGAR · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Adenoviral CDMOs →

Similar CDMOs

Vigene Biosciences
Rockville, MD
Signal Score: 72.5
AAV, Lentiviral, Adenoviral
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.2
AAV, Lentiviral, Plasmid DNA, Adenoviral
Exothera
Jumet, BE
Signal Score: 78.1
AAV, Adenoviral, Lentiviral
Advent Bioservices
London, UK
Signal Score: 78.1
AAV, Lentiviral, Adenoviral
ReiThera
Rome, IT
Signal Score: 71.1
Adenoviral, AAV